Tumor characteristics of ductal carcinoma in situ of breast visualized on [F-18] fluorodeoxyglucose-positron emission tomography/computed tomography: Results from a retrospective study

Table 1 Patients’ clinicopathological characteristics

Clinical characteristics		n	Pathological characteristics		n
Symptomatic presentation	Y/N	13/39	Comedo necrosis	Y/N	22/30
Palpability	Y/N	15/37	ER	Y/N	42/10
Biopsy device	CNB/VAB	20/32	PgR	Y/N	38/14
Image guidance	US/ST	45/7	HER2	Y/N	22/30
Calcification at MG	Y/N	27/25	Nuclear grade	1/2/3	42/82
Mass formation at MRI	Mass	8	Tumor size at pathology	Mean ± SD, range	41.4 ± 32.3, 1-150
	Non mass	42		< 20 mm	15
	Undetectable	2		≥ 20 mm	37
Lesion size at MRI	Mean ± SD, range	31.7 ± 20.0, 0-80.0
	< 20 mm	18
	≥ 20 mm	34

MG: Mammography; MRI: Magnetic resonance imaging; CNB: Core-needle biopsy; VAB: Vacuum-assisted biopsy; US: Ultrasonographic; ST: Stereotactic; ER: Estrogen receptor; PgR: Progesterone receptor; HER: Human epidermal growth factor receptor.

Table 2 Comparison between patients’ clinicopathological characteristics and positron emission tomography/computed tomography findings

		FDG uptake					SUVmax
		Negative	Positive	Percent	P1	P2	mean ± SD	P3	P4
Age (yr)	< 55	10	13	56.5%	0.785	0.373	1.88 ± 1.09	0.077	0.210
	≥ 55	14	15	51.7%			1.44 ± 0.66
Symptomatic presentation	Y	2	11	84.6%	0.012	0.019	2.36 ± 1.24	0.002	0.001
	N	22	17	43.6%			1.39 ± 0.59
Palpability	Y	3	12	80.0%	0.030	0.083	1.99 ± 0.87	0.024	0.853
	N	21	16	43.2%			1.49 ± 0.87
Biopsy device	CNB	5	15	75.0%	0.023	0.001	1.86 ± 0.68	0.012	0.031
	VAB	19	13	40.6%			1.49 ± 0.99
Image guidance	US	18	27	60.0%	0.040	0.545	1.73 ± 0.92	0.006	0.849
	ST	6	1	14.3%			0.99 ± 0.20
Calcification at MG	Y	15	12	44.4%	0.177	0.323	1.44 ± 0.66	0.107	0.214
	N	9	16	64.0%			1.84 ± 1.07
Mass formation at MRI	Y	3	5	62.5%	0.711	0.215	1.76 ± 0.72	0.348	0.253
	N	21	23	52.3%			1.61 ± 0.93
Lesion size at MRI (mm)	< 20	14	4	22.2%	0.001	0.001	1.24 ± 0.57	0.010	0.049
	≥ 20	10	24	70.6%			1.84 ± 0.97
Comedo necrosis	Y	9	13	59.1%	0.581	0.284	1.69 ± 0.85	0.634	0.301
	N	15	15	50.0%			1.59 ± 0.94
ER	Y	19	23	54.8%	1	0.249	1.67 ± 0.96	0.889	0.628
	N	5	5	50.0%			1.47 ± 056
PgR	Y	18	20	52.6%	1	0.608	1.64 ± 0.96	0.804	0.731
	N	6	8	57.1%			1.60 ± 0.72
HER2	Y	10	12	54.5%	1	0.681	1.65 ± 0.78	0.788	0.496
	N	14	16	53.3%			1.62 ± 0.98
Nuclear grade	1	20	22	52.4%	0.736	0.510	1.64 ± 0.93	0.898	0.718
	2.3	4	6	60.0%			1.61 ± 0.79
Tumor size at pathology	< 20	12	3	20.0%	0.002	0.708	1.19 ± 0.55	0.008	0.516
	≥ 20	12	25	67.6%			1.81 ± 0.97

¹Fisher’s exact test;

²Logistic regression analysis;

³Mann-Whitney’s U test;

⁴Multiple regression analysis. FDG: Fluorodeoxyglucose; SUVmax: Maximum standardized uptake value; MG: Mammography; MRI: Magnetic resonance imaging; CNB: Core-needle biopsy; VAB: Vacuum-assisted biopsy; US: Ultrasonographic; ST: Stereotactic; ER: Estrogen receptor; PgR: Progesterone receptor; HER: Human epidermal growth factor receptor.